increase, although those with more intact language and cognitive skills (Asperger type) could be missed in such young cohorts.
Current technologies can now elucidate the genetic cause in 10%-30% of people with ASD. 5, 6 Copy number variations (CNVs) involve relatively large segments of DNA; rare CNVs or other deleterious smaller sequence alterations occur in about 10% of idiopathic cases of ASD; 7 CNVs are now considered to cause ASD in some families. 8 About another 10% of individuals with ASD have known genetic conditions, the most common being fragile X syndrome (1%), tuberous sclerosis (1%) or Rett syndrome (0.5%). 9 Heritability can be estimated by comparing concordance in monozygotic and dizygotic twins. Early heritability estimates for ASD were high, indicating that many more inherited genetic elements remain to be identified. 5 To that end, a new international initiative 10 will sequence the genomes of 10 000 people with ASD, aiming to delineate all of the genetic factors involved. Genetic studies have led to a surprising revelation that ASD involves hundreds of genes, the identification of neuronal synapses as targets for therapeutic interventions, and the adoption of clinical microarrays as the standard of care for ASD diagnosis. 11, 12 Incomplete concordance in monozygotic twins and an increase in ASD diagnoses suggest the interaction of environmental and genetic factors. In utero exposures (including medications such as valproic acid, thalidomide, misoprostol, terbutaline or antidepressants), environmental neurotoxicants (e.g., pesticides) and infections (e.g., congenital rubella) have been hypothesized to increase the risk of ASD. 13 Even if confirmed through replication, these exposures would collectively explain only a small number of cases. Early hypotheses that suggested increased risk associated with vaccine exposure (i.e., through the measles-mumpsrubella vaccine or the preservative thimerosal) have been thoroughly disproved. 14, 15 A recent methodologically rigorous study of ASD in twins found lower heritability (37%) than previously thought, 16 suggesting that environmental factors that are shared by twins more than by other siblings (e.g., in utero or perinatal effects) are more influential than heritable factors. (Such influences could, however, still act at the level of the gene.)
How is ASD diagnosed?
The diagnostic assessment of ASD allows a physician to determine if a child meets the accepted ASD criteria (usually per Diagnostic and Statistical Manual of Mental Disorders [DSM] criteria), identify comorbid medical or genetic syndromes or psychopathology, and identify the patient's treatment needs. When Brian was 18 months, his parents expressed concerns to their pediatrician about his social development. Brian was born at term by spontaneous vaginal delivery, with weight and height at the 50th percentile and head circumference at the 97th percentile. Ultrasonography of his head showed no obvious abnormality, and there were no neonatal complications. Brian achieved early developmental milestones as expected: social smiling at eight weeks, babbling by six months and walking by one year. His first words were at 18 months. His mother noted that Brian did not always look when his name was called, had minimal interest in other children and had difficulty disengaging from certain toys, such as model trains on a track. The results of an audiology assessment were normal. The pediatrician completed a Modified Checklist for Autism in Toddlers with the mother, and Brian was found to be "at risk for autism." She referred Brian to the local infant development-early intervention service. Given his relative macrocephaly, she ordered magnetic resonance imaging of his head; the results were normal.
At 24 months, Brian's family returned to the pediatrician with additional concerns, despite some gains made with early intervention services. Although his language development was progressing (three-word phrases and more than 100 words), his speech had become repetitive (i.e., repeating questions, reciting dialogue from videos and using scripts mixed with spontaneous language in his everyday life). He seemed interested in other children, but he never approached on his own and needed much encouragement to respond positively to another child's approach, tending to play near other children with minimal interaction. He could stay for hours with his face to the carpet watching model trains. He did not engage in pretend play (e.g., "feeding" stuffed animals). The pediatrician observed Brian playing repetitively with toys in the waiting room and interacting minimally with other children. Eye contact was present but variable. She attempted to draw Brian's attention to a toy on a shelf by engaging his gaze and shifting to look at the toy, but Brian failed to follow the look, even when she also pointed. Another noisy child led to significant stress for Brian, who tensed his body, flapped his arms and repeated a script from a favourite cartoon as he walked away.
The pediatrician diagnosed autism spectrum disorder (ASD), based on DSM-V criteria. She ordered a genomic microarray and referred the family to the local speech and language services and the autism early intervention program. The microarray report revealed a deletion of chromosome 1p36.23-p36.32 and suggested referral to a clinical geneticist. The geneticist advised the pediatrician to order certain tests in advance, including cardiac and renal ultrasonography, thyroid testing and referral to an ophthalmologist. Renal ultrasonography showed a vesico-ureteral malformation, and the pediatrician referred Brian to urology. Thyroid studies suggested hypothyroidism, prompting referral to pediatric endocrinology.
Brian was seen by a clinical geneticist several months later. The deletion was not found in either parent and was presumed to be the cause of Brian's difficulties. The geneticist reassured parents about the low risk of recurrence in a sibling.
Commentary
This diagnosis of ASD was made by the child's pediatrician based on DSM criteria, and the child was referred to community services. Practices related to diagnosis vary among provinces and territories and between urban and rural settings. In some cases, each child with a possible ASD diagnosis can access a multidisciplinary team involving a primary care physician, psychologist, and perhaps a speech-language pathologist or occupational therapist or both. Elsewhere, an expert clinician (primary care physician or psychologist) provides the diagnosis and refers to other services. Any of these routes to care could be appropriate, based on the local system and resources, as long as an experienced clinician trained and competent in this area is responsible for guiding the process.
shows the typical paths to diagnosis, starting with concerns (including "red flags") raised by parents, teachers, childcare providers, early childhood educators, family physicians or pediatricians. Primary care providers then determine whether an assessment is needed for ASD or another developmental issue. A detailed developmental history is collected from the parents, and additional information is collected from teachers, early childhood educators and health professionals. It is essential for the primary care provider to spend time with the child engaged in structured play activities that assess social-emotional relatedness, the ability of the child to respond to and direct the attention of others, and his or her use of gestures, imitation, imagination and conversation. Multiple prospective and retrospective studies support the recommendations of comprehensive reviews and guidelines on diagnosis. 18, 19 Among people with ASD, 10%-25% have an associated "medical disorder" (e.g., a genetic syndrome such as fragile X syndrome or tuberous sclerosis, teratogenic exposure or neurologic disorder). 20, 21 Assessment of an individual with ASD should include obtaining thorough prenatal, perinatal, medical and family histories, and a physical examination to document growth parameters (particularly head circumference) and the presence or absence of dysmorphic features.
In 2009, the Canadian College of Medical Geneticists recommended genome-wide microarray analysis, rather than karyotyping, as a firstline laboratory investigation for individuals with ASD 11 because of its enhanced detection of chromosome abnormalities at greater resolution and because a single microarray assay can reveal the equivalent of hundreds or thousands of targeted (probe) investigations. Positive findings may be helpful in a family's search for explanations, provide a genetic handle for predicting recurrence, alert physicians to certain risks associated with known genomic alterations, and may eventually allow targeted therapies. 8, 9 Other laboratory investigations should include testing for fragile X syndrome and sequencing of the PTEN gene for individuals with a head circumference of three or more standard deviations above the mean. Fragile X syndrome is relatively common and has specific health and reproductive implications for family members. Mutations in the PTEN gene, although rare, indicate a need for additional tumour surveillance for carriers. 21 Mutations in the MECP2 gene are rare (< 2%) among females with ASD and have only been identified among those with comorbid intellectual disability. Mutation testing should be considered for females with ASD and intellectual disability, especially those with clear regression in development. 22 Recognition of such X-linked mutations (sometimes leading to a Rett syndrome phenotype) is important for prognosis and the risk of recurrence, distinct from that associated with ASD.
Additional investigations such as electroencephalography or metabolic testing should be guided by clinical indicators. The routine use of neuroimaging remains controversial (because most children require sedation or general anesthetic), but we recommend neuroimaging at least for patients with "complex ASD"
23 (e.g., substantial dysmorphology, microcephaly and/or seizures).
24 Table 1 summarizes the recommended clinical work-up for patients with ASD at our centres.
The key to accurate diagnosis is a clear understanding of skills and deficits in social communication and the extent to which these can be accounted for by the child's overall developmental level or by the presence of other disorders. The DSM-IV-TR (DSM text revision); criteria for autism have shown good sensitivity and specificity. 28 Diagnostic difficulties can arise if the child is very young, has a mental age of less than 24 months or is severely intellectually disabled. Relatively intact language and intellectual abilities may lead to later identification. In such Review CMAJ, April 15, 2014, 186 (7) 511 cases, assessment of cognitive, social-emotional and communicative skills is invaluable.
The fifth edition of DSM (DSM-5) 29 combines autistic disorder, Asperger disorder, childhood disintegrative disorder and pervasive developmental disorder not otherwise specified into a single omnibus category termed "ASD." This change reflects how the symptoms of these disorders represent a continuum from mild to severe rather than qualitatively distinct disorders. 3 0 Public concerns over whether some higher-functioning individuals would be excluded from diagnosis, and thereby from benefits and supports, have not been supported by field trials that compared diagnoses made under DSM-IV and DSM-5. 31 Various instruments may be used to facilitate structured observation or systematic history-taking. The Autism Diagnostic Observation Schedule 32 (specificity: 0.72-1.0; sensitivity: 0.72-0.98, depending on age and severity 33 ) and the Childhood Autism Rating Scale 2 34 (sensitivity and specificity: each 0.82-0.95, depending on age and severity for cut-off scores of 25.5 35 ) have shown good reliability and validity. The Autism Diagnostic Interview-Revised 36 may assist with obtaining a systematic patient history in specialized settings.
Review

How can we detect ASD early?
Although more than 80% of children with ASD show clear behavioural signs by two years of age and a diagnosis can be made reliably this early, the average age at diagnosis is about four years. 1 Earlier diagnosis would alleviate prolonged concerns of many families and expedite opportunities to benefit from specialized interventions, 37, 38 thereby reducing costs to families and society. 39 Parental reports, analyses of home videos and, more recently, prospective studies of infants at increased risk of ASD have identified numerous red flags that distinguish toddlers with ASD from those with typical development or other developmental delays (Box 4). These signs were recently analyzed in a comprehensive literature review. 4 1 Earlier in infancy, ASD may be reflected by atypical regulatory functions related to sleep, eating and emotions.
The most effective strategy for identifying children with early signs of ASD is still debated. The American Academy of Pediatrics and others have recommended universal screening at 18 and 24 months 19 using standardized tools, whereas professional groups in Canada (e.g., Canadian Paediatric Society) tend to stress developmental surveillance, monitoring parents' concerns and observation of the child, with or without standardized tools. In parts of Canada, surveillance has been enhanced by the use of broadband developmental screens, such as the Nipissing District Developmental Screen, 42 and other standardized approaches to documenting parental or clinician concerns. 43 Infants at high risk, such as siblings of children with ASD, should be monitored closely by their family doctor or pediatrician, and there should be a lower threshold for further assessment within primary care or by specialists. 4, 16 Although a comprehensive review of screening for ASD is beyond the scope of this paper (for more detail, see Zwaigenbaum 18 ), two measures -the Modified Checklist for Autism in Toddlers (M-CHAT) 44 and the Infant-Toddler Checklist (ITC) 45 -have good psychometric properties for screening and are recommended for use. The ITC has a sensitivity of 0.86-0.89 and a specificity of 0.75-0.77, with a positive predictive value (PPV) of 0.65-0.80. 45, 46 The M-CHAT has a sensitivity of 0.77-0.97 and a specificity of 0.38-0.99, with a PPV of 0.06-0.92. 44, [47] [48] [49] [50] [51] [52] Both have been used to screen for ASD among children in community pediatricians' offices. 44, 53 The Social Communication Questionnaire, another screening tool, is appropriate for children above three years of age but not younger. 54, 55 Evidence prompts us to recommend a multistage process (Figure 1 ) in which a network of par- • Under-or over-reaction to sounds or other forms of sensory stimulation
• Delayed fine and gross motor skills, atypical motor control (e.g., reduced muscle tone, reduced postural control for age)
• Repetitive motor behaviours, atypical posturing of limbs or digits ents and community professionals contribute to the surveillance for ASD red flags, leading to referral for general developmental assessment by community physicians or other providers (e.g., speech language pathologists) ( Table 1) . Community physicians play an essential role in identifying early signs of ASD and ensuring timely diagnosis. The greatest impact on outcome will come from careful attention to parents' concerns, observing early social and communication skills (e.g., interaction with parents and response to simple social games), immediate referral to available intervention services (e.g., infant development and/or speech-language services), and timely referrals for specialized assessments and interventions. 40 
Which comorbidities characterize the autism spectrum?
A number of medical and psychiatric comorbidities have been identified in patients with ASD. These comorbidities and the epidemiologic evidence supporting them are outlined in Appendix 1 (available at www .cmaj.ca/lookup /suppl /doi :10.1503 /cmaj .121756/-/DC1). Children with ASD should be monitored for comorbid psychiatric disorders. Clinicians are becoming aware of the frequency of attention deficit hyperactivity disorder (ADHD), anxiety and mood disorders among these children; 56,57 these conditions require identification and intervention as early as possible.
What treatments and interventions are available, and are they effective?
The goal of existing interventions is to facilitate the acquisition of skills, remove barriers to learning and improve functional skills and quality of life.
Behavioural interventions
Current best practices for preschool-aged children with ASD include a focus on improving language, cognitive and adaptive skills using applied behaviour analysis (ABA) techniques. 58 Applied behaviour analysis refers to the application of empirically derived learning principles (i.e., the antecedent-behaviour-consequence contingency) to produce meaningful changes in behaviour. 59 Such strategies are carefully engineered and implemented through a variety of approaches (e.g., discrete trial teaching to more naturalistic learning contexts) to teach skills and reduce problem behaviour. Applied behaviour analysis interventions can be provided in a variety of settings (e.g., home, specialized treatment centres, specialized or public schools) by a range of front-line therapists, ideally supervised by a psychologist or board-certified behaviour analyst who specializes in ASD.
A recent overview of meta-analyses 60 found significantly enhanced outcomes associated with early intensive ABA-based treatment (typically for 2-3 yr) in four of five included meta-analyses (effect sizes 0.30 to > 1); these findings have since been bolstered by a sixth meta-analysis. 61 Gains appear to be greatest in verbal intelligence quotient (IQ) and language communication domains, 62, 63 for children with stronger pretreatment skills, if treatment is started earlier, 64 and with greater intensity or duration of intervention. [60] [61] [62] 64 These gains achieved in various domains have been summarized in a recent Cochrane review. 63 Although the overall quality of evidence is low, it is the best evidence available.
A recent study in Ontario reported predictors of outcome that account for some heterogeneity in treatment response. 65 A recent RCT supported the efficacy of ABA-based intervention in toddlers by showing improvements in IQ, adaptive skills and diagnostic classification. 37 Models vary, notably by how ABA principles are implemented, but everyday contexts (e.g., free play v. "tabletop") and activities based on the child's interests (v. therapist's agenda) have advantages, including greater generalization of learning. 66 Questions remain about which forms and intensities of treatment are most effective for which children. Research on non-ABA-based treatments is sparse and shows limited efficacy. 67 Translation of evidence-based intervention into community practice is being evaluated, including in Canada. 68 A key question is whether effective high-quality programs can be less costly and more sustainable; the findings from Nova Scotia are promising. 38 Studies of the effectiveness of treatment programs for older children, youth and adults with ASD are scarce. Benefits have been reported for structured teaching practices, including ABAbased interventions, for a wide range of skill deficits and maladaptive behaviours. 
Biomedical interventions
Despite advances in pharmacologic therapy for ASD over the past two decades, there are still no agents that address the core symptoms of the disorder. For individuals aged more than five years, large clinical trials have addressed the efficacy and safety of the major classes of medications used in the clinic. 69, 70, 71 A few systematic reviews are available [72] [73] [74] supporting the use of pharmacologic agents for associated symptoms. Table 2 Review presents the level of evidence, adverse events and effect sizes for medications used to treat ASD-related behaviours and symptoms.
Irritability and impulsive aggression
Risperidone and aripiprazole, two atypical antipsychotic medications, are the only medications with an indication by the US Food and Drug Administration for ASD-related symptoms. Large RCTs have shown their efficacy for irritability. 69, 75 Cochrane systematic reviews have shown decreases in irritability using the Aberrant Behavior Checklist subscale with respiridone 72 (8.09 points v. placebo) and aripiprazole (6.17 points v. placebo). 73 Data from open-label and small RCTs suggest that other typical and atypical antipsychotics may be useful (Table 2 ).
Hyperactivity and inattention
Stimulants and atomoxetine may be effective for treating ADHD-like symptoms in patients with ASD, albeit with smaller effect and more adverse outcomes than in children with ADHD alone. 71, 77 Early data suggest a similar role for α-2 adrenergic agonists, such as clonidine and guanfacine. 79 Repetitive behaviours Not all repetitive behaviours or restrictive interests in individuals with autism are interfering, and some behaviours can be shaped into functional skills. The effectiveness of selective serotonin reuptake inhibitors (SSRIs) for repetitive behaviours has been questioned: the largest clinical trial for ASD found no effect of citalopram, and its use was associated with adverse effects. 70 Risperidone and aripiprazole significantly reduced repetitive behaviours in children with ASD, 75 83 and which require medical intervention (see recent guideline 74 ).
Alternative medications
Alternative or complementary approaches are often pursued by families, despite a lack of empirical support. Although some of these approaches have theoretical promise and deserve further research (e.g., omega-3 fatty acids, B complex vitamins, special diets), others are potentially harmful (e.g., chelation) or simply expensive and ineffective (e.g., secretin).
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Outcomes
Studies of outcomes among adults with ASD consistently show low to modest levels of independence and/or social inclusion among both higher-and lower-functioning individuals. [85] [86] [87] Core phenotypic features and challenging behaviours persist, although some problems can improve over time. Some improved outcomes may be because of more inclusive and specialized educational programs. The level of verbal communication and IQ before five years of age are the strongest predictors of outcome.
Future directions
We have come to understand ASD as a remarkably heterogeneous constellation of conditions that covary with other disabilities and disorders (e.g., intellectual disability, epilepsy, ADHD, anxiety disorders) and various medical problems. Recent discoveries of underlying genomic factors have shown great complexity and implicate various networks of causal factors. Biological models highlight the likely involvement, at least for a subgroup of patients, of processes associated with synaptic integrity and plasticity. New experimental therapeutics hold promise for the treatment of core symptoms and have the potential to alter developmental trajectories. Treatments in animal models carrying single gene mutations for disorders associated with ASD are particularly promising, 84, 88, 89 and most are now in clinical trials. Future research should focus on how we can better match interventions to child and family characteristics through personalized medicine over the lifetime of the patient.
